Background
Methods
Study population
DNA extraction and SNP genotyping
Statistical analysis
Results
Clinical characteristics of the cohort
Variables | Cases (n = 257) | Controls (n = 537) |
P value |
---|---|---|---|
Female sex, No. (%) | 35 (14) | 131 (25) | 0.001 |
Median Age at index infarction, y (IQR) | 60 (53–68) | 61 (52–66) | 0.100 |
Cardiovascular risk profile | |||
Body mass index (kg/m2), (IQR) | 27.2 (25–29) | 26.7 (24–29) | 0.400 |
Smoking (pack year), (IQR) | 25 (5–41) | 25 (6–42) | 0.200 |
Smoking, No. (%) | |||
Never | 38 (16) | 108 (20) | 0.300 |
Past | 69 (28) | 133 (25) | |
Current | 136 (56) | 290 (55) | |
Alcohol per week, (unit*, IQR) | 6 (1–15) | 3 (0–9) | <0.001 |
Alcohol units per week (categorized), No. (%) | |||
Non-drinkers | 46 (19) | 143 (27) | <0.001 |
Normal (1–7) | 90 (38) | 242 (46) | |
Moderate High (8–14) | 41 (17) | 70 (13) | |
High (>15) | 60 (26) | 73 (14) | |
Diabetes, No. (%) | 30 (12) | 47 (9) | 0.200 |
Hypertension, No. (%) | 102 (41) | 184 (35) | 0.070 |
COPD, No. (%) | 12 (5) | 30 (6) | 0.700 |
Hypercholesterolemia, No. (%) | 97 (39) | 165 (31) | 0.023 |
Stroke, No. (%) | 18 (7) | 26 (5) | 0.200 |
Atrial fibrillation, No. (%) | 16 (7) | 10 (2) | 0.006 |
Depression, No. (%) | 28 (11) | 65 (12) | 0.700 |
Epilepsy, No. (%) | 4 (2) | 5 (1) | 0.500 |
Family History, No. (%) | |||
Sudden death | 94 (40%) | 128 (25%) | <0.001 |
Myocardial infarction | 90 (40%) | 195 (38%) | 0.600 |
Stroke | 36 (16%) | 75 (15%) | 0.600 |
Medication before MI¶, No. (%) | |||
β-blockers | 20 (8) | 43 (8) | 0.900 |
Statins | 55 (22) | 65 (12) | <0.001 |
ACE/ARB blockers | 50 (21) | 90 (17) | 0.200 |
Aspirin | 28 (12) | 40 (8) | 0.060 |
Common genetic variants associated with VF
Locus | SNP | RA | RAF (Cases/Controls) | OR | 95% CI | P | Nearest gene symbol | |
---|---|---|---|---|---|---|---|---|
1& | 1q21 | rs6666258 | C | 0.31/0.33 | 0.91 | 0.72–1.15 | 0.400 | |
2 | 1q24 | rs3903239 | C | 0.46/0.49 | 0.85 | 0.68–1.07 | 0.200 |
PRRX1 [9] |
3 | 3p25 | rs4642101 | G | 0.61/0.62 | 0.99 | 0.79–1.25 | 0.900 |
CAND2 [22] |
4#* | 3p21 | rs6795970 | A | 0.00/0.00 | – | – | – |
SCN10A [17] |
5&* | 4q25 | rs2200733 | T | 0.08/0.08 | 0.96 | 0.65–1.42 | 0.900 | |
6& | 4q25 | rs2634073 | A | 0.14/0.15 | 0.88 | 0.65–1.20 | 0.400 |
PITX2 [9] |
7& | 4q25 | rs6843082 | G | 0.16/0.18 | 0.87 | 0.66–1.17 | 0.400 | |
8 | 4q25 | rs1448818 | G | 0.26/0.24 | 1.13 | 0.89–1.43 | 0.300 |
PITX2 [21] |
9& | 4q25 | rs10033464 | T | 0.76/0.94 | 0.79 | 0.53–1.17 | 0.300 | |
10 | 4q25 | rs17570669 | T | 0.06/0.08 | 0.74 | 0.48–1.12 | 0.200 |
PITX2 [21] |
11 | 4q25 | rs2723288 | T | 0.29/0.28 | 1.08 | 0.86–1.35 | 0.500 |
PITX2 [21] |
12 | 4q25 | rs4400058 | A | 0.08/0.09 | 0.80 | 0.54–1.18 | 0.300 |
PITX2 [21] |
13 | 4q25 | rs6838973 | T | 0.43/0.44 | 0.95 | 0.76–1.18 | 0.700 |
PITX2 [21] |
14 | 4q25 | rs3853445 | C | 0.26/0.25 | 0.99 | 0.78–1.27 | 0.900 |
PITX2 [21] |
15 | 5q31 | rs2040862 | T | 0.18/0.16 | 1.15 | 0.87–1.53 | 0.300 |
PITX2 [21] |
16 | 6q22 | rs13216675 | T | 0.68/0.69 | 0.95 | 0.75–1.18 | 0.600 |
GJA1 [22] |
17 | 7q31 | rs3807989 | G | 0.41/0.42 | 1.00 | 0.81–1.25 | 0.900 |
CAV1 [9] |
18 | 9q22 | rs10821415 | A | 0.39/0.39 | 0.97 | 0.78–1.20 | 0.800 |
C9ORF3 [9] |
19 | 10q22 | rs10824026 | G | 0.13/0.15 | 0.85 | 0.62–1.16 | 0.300 |
MYOZ1 [9] |
20 | 10q24 | rs12415501 | T | 0.15/0.16 | 0.92 | 0.68–1.23 | 0.600 |
NEURL [22] |
21 | 12q24 | rs10507248 | T | 0.75/0.74 | 1.05 | 0.82–1.33 | 0.700 |
TBX5 [22] |
22 | 14q23 | rs1152591 | T | 0.51/0.48 | 1.11 | 0.89–1.38 | 0.300 |
SYNE2 [9] |
23 | 15q24 | rs7164883 | G | 0.17/0.13 | 1.28 | 0.96–1.70 | 0.090 |
HCN4 [9] |
24 | 16q22 | rs2106261 | A | 0.18/0.17 | 1.09 | 0.83–1.44 | 0.500 |